What is Hemispherian?
Hemispherian is a specialized pharmaceutical enterprise dedicated to the development of a novel class of small molecule drugs known as GLIX. These compounds are engineered to target the TET2 enzyme, effectively activating the DNA damage response to induce cancer cell death. The company's primary focus is the treatment of glioblastoma multiforme, a highly aggressive and lethal form of brain cancer. Beyond its therapeutic pipeline, Hemispherian is actively developing a companion diagnostic tool designed to optimize patient selection, thereby increasing the probability of therapeutic success. This dual-pronged approach—combining targeted drug therapy with precision diagnostics—positions the company as a high-potential player in the precision medicine sector.
How much funding has Hemispherian raised?
Hemispherian has raised a total of $14.3M across 4 funding rounds:
Multiple Rounds
$14.3M
Angel/Seed (2022): $1.4M with participation from Meneldor
Private Equity (2022): $7.5M led by The European Innovation Council
Grant (2022): $2.5M supported by The European Innovation Council
Series A (2022): $2.9M featuring Kistefos, Meneldor, and Kvantia
Key Investors in Hemispherian
Kistefos
A private investment firm based in Oslo, Norway, managing a diversified portfolio across sectors including shipping, technology, and financial services.
Meneldor
A specialized investment firm focusing on early-stage biotech and pharmaceutical companies, conducting rigorous scientific and market evaluations.
The European Innovation Council
An institutional body providing critical support and grants to innovative European companies to foster research and development.
What's next for Hemispherian?
With the recent capital infusion, Hemispherian is expected to prioritize the advancement of GLIX1 through the final stages of preclinical testing. The strategic roadmap includes finalizing the companion diagnostic tool, which is essential for identifying the patient populations most likely to respond to the GLIX therapy. As the company moves toward potential clinical trials, the focus will shift toward establishing robust clinical data and securing further partnerships to facilitate the transition into human trials. The management team is likely to leverage the expertise of its current investor base to navigate the complexities of the global pharmaceutical market, ensuring that their innovative approach to DNA damage response reaches the clinical stage with maximum efficacy and safety profiles.
See full Hemispherian company page
